A fecal microbiota transplant (FMT) typically costs somewhere between a few hundred dollars and roughly $10,000 out of pocket in the United States, depending on how the procedure is delivered, where it takes place, and how the donor stool is sourced. One cost-effectiveness analysis pegged the base-case cost of FMT by colonoscopy at around $5,250, while outpatient procedures and capsule-based approaches can come in considerably lower. But the sticker price is only part of the story, because the real financial picture involves donor screening, facility fees, whether you are an inpatient or outpatient, and whether your insurance covers any of it.
What Goes Into the Total Bill
When people ask what a fecal transplant costs, they are usually imagining a single line item. In reality, the bill is assembled from several distinct charges that vary independently. The donor stool itself has a price, the procedure used to deliver it has a price, the facility where it happens has a price, and the physician’s professional fee sits on top of all of that. How those components shake out depends largely on whether your center uses a stool bank or screens a patient-directed donor, and whether the transplant goes in via colonoscopy, enema, nasogastric tube, or oral capsules.
One study comparing a stool bank approach to patient-directed donors found that using pre-screened material from a universal donor bank cost about $485 per preparation, while screening and preparing stool from a patient-chosen donor averaged roughly $1,190. That difference alone can swing the total bill by several hundred dollars before the procedure even begins.1PubMed Central. Reducing Cost and Complexity of Fecal Microbiota Transplantation Using Universal Donors for Recurrent Clostridium difficile Infection
How Delivery Method Affects Price
The most common delivery routes for FMT are colonoscopy, oral capsules, enema, and nasogastric tube. Each carries different procedural costs, sedation requirements, and facility fees, so the choice of route meaningfully moves the total price.
Colonoscopy is the most frequently studied delivery method and, in a U.S. cost-effectiveness model, came in at around $5,250 for the full episode of care. Oral capsules were also considered cost-effective at a somewhat higher total when quality-adjusted outcomes were factored in, with an incremental cost-effectiveness ratio of about $31,200 per quality-adjusted life year compared to colonoscopy.2PubMed. Fecal Transplants by Colonoscopy and Capsules Are Cost-Effective Strategies for Treating Recurrent Clostridioides difficile Infection Capsules avoid the sedation and endoscopy suite fees that come with colonoscopy, which can make them cheaper in pure procedural terms even if the stool material itself costs the same.
A U.K. economic model painted a similar picture from a different currency. FMT delivered by nasogastric tube was the least expensive strategy at roughly £8,900 per patient, while FMT by colonoscopy came in at about £11,700. Both crushed the cost of repeated vancomycin courses, which ran approximately £17,300 per patient in that model. Fidaxomicin, another antibiotic option, was also more expensive and less effective than either FMT route.3The Lancet. Economic evaluation of Faecal microbiota transplantation compared to antibiotics for the treatment of recurrent Clostridioides difficile infection The takeaway is that the cheapest delivery route can vary by healthcare system, but FMT consistently costs less than drawn-out antibiotic regimens no matter which route you pick.
Donor Screening Is a Bigger Cost Driver Than Most People Realize
Before anyone’s stool goes into anyone else’s body, it has to be screened extensively. Donors are tested for HIV, hepatitis A through C, syphilis, drug-resistant bacteria, parasites, and a long list of other transmissible infections. Blood, stool, urine, and swab samples are all part of the standard workup.4Open Forum Infectious Diseases. Extended Screening Costs Associated With Selecting Donors for Fecal Microbiota Transplantation for Treatment of Metabolic Syndrome-Associated Diseases This is not a one-time expense either. Active donors get rescreened regularly, sometimes every few months.
A Dutch study tracked the real-world costs of maintaining a donor program and found that the initial round of blood and stool testing alone ran about €846 per donor candidate. But because most candidates fail screening, and active donors need repeated rescreening, the total annual cost per active donor climbed to roughly €2,800 in a standard protocol and as high as €5,400 when frozen-stool protocols requiring more frequent testing were used.5PubMed Central. Challenges and costs of donor screening for fecal microbiota transplantations These costs get baked into the price of the stool preparation, which is why stool banks charge what they charge. When a center uses a patient-directed donor instead of a bank, those screening costs land more directly on the patient or their insurance.
The screening intensity increased after a 2019 FDA safety alert involving two immunocompromised patients who developed serious infections from drug-resistant E. coli transmitted through FMT stool. One of those patients died. The FDA now recommends testing for multidrug-resistant organisms and excluding high-risk individuals from donating.6PubMed Central. Adverse events of fecal microbiota transplantation: a meta-analysis of high-quality studies Tighter screening is obviously good for safety, but it also raises the per-dose cost of stool material.
The Inpatient-Outpatient Gap
Where the procedure happens matters enormously to the final bill. A pediatric study found that inpatient FMT charges ranged from about $2,700 to $9,300 for just the days when the transplant was performed, not counting the rest of the hospital stay. Outpatient charges, by contrast, ranged from zero dollars for patients who already had a feeding tube and could receive the transplant at home using enemas, up to about $1,800 for those done via outpatient colonoscopy.7Pediatric Annals. Inpatient Versus Outpatient Fecal Microbiota Transplantation for Pediatric Clostridium difficile Infection
That gap makes intuitive sense. Inpatient procedures carry room charges, nursing costs, and monitoring fees that outpatient settings avoid. If you are already hospitalized for a severe C. difficile infection, those costs pile onto an already expensive stay. For people whose health allows an outpatient procedure, the savings can be dramatic.
How FMT Stacks Up Against Prolonged Antibiotics
The real financial question for most patients is not “what does FMT cost in isolation?” but rather “what does it cost compared to the alternative?” For recurrent C. difficile infection, the alternative is usually round after round of antibiotics, each with its own failure rate, each triggering another clinic visit or hospital admission when the infection bounces back.
Multiple economic evaluations across different countries have converged on the same conclusion: FMT is cheaper than extended antibiotic therapy for recurrent C. diff. A U.S. model found that the most cost-effective strategy for someone with a first recurrence was to use FMT at that point rather than cycling through more antibiotics, with a cost-effectiveness ratio of about $27,100 per quality-adjusted life year. In simulations, this strategy was cost-effective about 90% of the time.8PubMed Central. Cost-effectiveness of Fecal Microbiota Transplantation for First Recurrent Clostridioides difficile Infection
A European trial-based evaluation was even more striking. Patients randomized to FMT had roughly €1,650 lower hospital costs over six months than those receiving vancomycin alone, driven by fewer readmissions and less medication use. The analysis found that FMT remained cost-effective as long as the treatment cost stayed below about €3,100 for a full two-component course.9Journal of Hospital Infection. Cost-effectiveness of faecal microbiota transplantation compared with vancomycin monotherapy for early Clostridioides difficile infection In the U.K. model mentioned earlier, vancomycin was dominated outright, meaning it cost more and produced worse health outcomes than FMT by every delivery route studied.3The Lancet. Economic evaluation of Faecal microbiota transplantation compared to antibiotics for the treatment of recurrent Clostridioides difficile infection
The pattern is consistent enough that the question has shifted from “is FMT cost-effective?” to “how early should we use it?” Several researchers have argued it should be offered at the first recurrence rather than waiting for a second or third, partly on economic grounds.
The Downstream Savings Are Substantial
Beyond the procedure itself, FMT can dramatically cut ongoing healthcare costs for patients who had been trapped in cycles of recurrent infection. A Dutch study tracked total healthcare spending before and after FMT and found that annual costs per patient dropped by about 42%, falling from roughly €56,400 to around €32,800. The biggest driver was fewer and shorter hospital admissions: median inpatient days fell from 31 to 8, and ICU costs plummeted by about 91%.10PubMed Central. Cost savings following faecal microbiota transplantation for recurrent Clostridium difficile infection
These numbers reflect the reality that recurrent C. diff is not just unpleasant but devastatingly expensive. Patients bounce in and out of hospitals, require costly IV antibiotics, and sometimes end up in intensive care. A single successful FMT can break that cycle, so even if the upfront procedure costs several thousand dollars, the system-level savings can be many times that amount within the first year.
Insurance Coverage Remains Patchy
Whether your insurance covers FMT depends on your plan, your insurer, your diagnosis, and sometimes your state. The procedure has been used under FDA enforcement discretion for recurrent C. difficile infection since 2013, meaning the FDA has allowed it without formal drug approval for that specific indication. This regulatory gray zone creates headaches for billing departments. There is no single universal billing code for FMT itself; instead, the procedure is often billed under the code for whichever delivery method is used, such as a colonoscopy code, plus the stool preparation as a separate charge.
Some insurers cover FMT for recurrent C. diff without much pushback, especially after two or more documented recurrences. Others require prior authorization, letters of medical necessity, or appeals. Coverage for any use beyond C. diff is even less predictable, since off-label applications are still considered experimental by most payers. Out-of-pocket costs for patients vary widely depending on these coverage decisions, and the financial inaccessibility of the procedure is a documented reason some patients look for alternatives.11PubMed Central. Procedure, Screening, and Cost of Fecal Microbiota Transplantation
Why Some People Try DIY Fecal Transplants
The combination of high upfront costs, inconsistent insurance coverage, and limited access to FMT centers has pushed some patients toward do-it-yourself approaches. Surveys of people who have performed home FMT found that prohibitive costs and frustration with the lack of effective treatment were key motivations.12PubMed Central. Understanding the Scope of Do-It-Yourself Fecal Microbiota Transplant Online communities share instructions, and the materials themselves (an enema kit and a willing donor) cost almost nothing.
The risks, though, are real. Home-prepared stool is almost never screened to the standard used in clinical settings. That means the recipient could be exposed to HIV, hepatitis, drug-resistant bacteria, or parasites without knowing it. The serious adverse event rate for clinical FMT, where donors are rigorously screened, is about 1.4%, with nearly all serious complications occurring in patients who already had compromised gut barriers or immune systems and received the transplant via the upper gastrointestinal tract.13PubMed. Systematic review: the global incidence of faecal microbiota transplantation-related adverse events from 2000 to 2020 Without professional screening and medical oversight, that risk almost certainly goes up. The cost savings of a DIY approach are real, but so is the possibility of a catastrophic outcome that no amount of money can fix.
Costs for Conditions Beyond C. Diff
Most cost data for FMT comes from studies on recurrent C. difficile, because that is where the strongest evidence exists and where FMT is most commonly performed. But researchers are actively investigating FMT for ulcerative colitis, irritable bowel syndrome, metabolic syndrome, and other conditions. The economics look different for these uses.
For ulcerative colitis, a cost-effectiveness analysis found that adding FMT to standard treatment could range from cost-saving to an incremental expense depending on how many FMT sessions were needed. With three administrations per treatment course, the combination was cost-effective about 91% of the time at a commonly used willingness-to-pay threshold. With six administrations, that dropped to about 67%.14PubMed. Fecal microbiota transplantation for patients with active ulcerative colitis: A cost-effectiveness analysis The appeal of FMT for conditions like ulcerative colitis partly lies in the prospect of reducing long-term immunosuppressive medications, which carry their own substantial costs and side effects.15PubMed. Fecal microbial transplant for inflammatory bowel disease
Insurance coverage for these off-label uses is rare. If you are considering FMT for anything other than recurrent C. diff, you should expect to pay out of pocket or through a clinical trial, where the research team typically covers the cost.
FMT in Veterinary Medicine
If the cost of human FMT feels steep, it is worth knowing that the same concept has gained traction in veterinary practice, particularly for horses and dogs with gastrointestinal infections. In equine medicine, fecal transplantation has been described as faster and cheaper than traditional antibiotic therapy, with the added benefit of avoiding dysbiosis and antibiotic resistance.16Veterinary Science Today. Using fecal microbiota transplantation for animal health (review) Veterinary FMT is far less regulated than the human version, which keeps costs lower but also means quality control varies wildly between clinics. Some equine veterinarians perform the procedure for a few hundred dollars, while specialty animal hospitals charge more. The principles are the same as in human medicine: screen the donor, prepare the material, deliver it to the gut. The regulatory and insurance apparatus that inflates human costs simply does not exist in the veterinary world.
How FDA-Approved Alternatives Change the Landscape
In late 2022 and 2023, the FDA approved two microbiota-based therapies for recurrent C. difficile infection: Rebyota (fecal microbiota, live-jslm) and Vowst (fecal microbiota spores, live-brpk). These are not traditional FMT but manufactured products derived from donor stool and processed under pharmaceutical-grade conditions. Their arrival has started to reshape the cost conversation.
Rebyota is administered as a single rectal dose, while Vowst is taken as a course of oral capsules. As manufactured biologics, they carry pharmaceutical price tags. Published list prices for Vowst have been reported in the range of $17,500 per course, and Rebyota’s wholesale acquisition cost is also in the thousands. These products offer standardized quality and clear regulatory status, which may make insurance coverage easier to obtain, but their sticker prices are higher than traditional FMT performed at many centers. Whether they prove cost-effective compared to traditional FMT over the long run is still being studied.
For patients, the practical effect is that the menu of options has expanded. Traditional FMT through a stool bank and colonoscopy remains available at many academic centers, often at a lower direct cost than the new branded products but with more variable insurance coverage. The FDA-approved alternatives offer convenience and regulatory clarity at a premium. Your gastroenterologist can help you weigh the tradeoffs based on your insurance situation and clinical history.